AVNT · Avient Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Avient reported Q2 adjusted EPS of $0.96, beating $0.89 guidance on stronger-than-expected organic volume, with record 18.3% adjusted EBITDA margins and 20% adjusted EPS growth, while raising full-year 2026 adjusted EPS guidance to $3.10–$3.25 (from $2.93–$3.17) and adjusted EBITDA to $575–$603M; however, transportation demand remains soft and healthcare is still weighed by customer inventory rebalancing.
- + Q2 adjusted EPS of $0.96 beat guidance of $0.89, driven by better-than-expected volume growth.
- + Adjusted EBITDA margin reached a record 18.3%, expanding 110 basis points year-over-year; organic sales grew 4.3%.
- + Full-year 2026 adjusted EPS guidance raised to $3.10–$3.25 (from $2.93–$3.17), representing 10–15% growth; adjusted EBITDA raised to $575–$603M.
- + Asia organic sales grew 18% in Q2 with double-digit growth in both segments, driven by electronics, HPC, and functional additives.
- + Repaid $50M of debt in Q2 ($200M over the last 12 months); 2026 free cash flow guidance raised to $210–$230M.
- − Transportation demand remains soft and is not expected to improve through the second half.
- − Healthcare results are weighed down by customer inventory rebalancing in drug delivery and remote monitoring, with growth only expected to return in the second half.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVNT
this stock
Avient Corp
|
$3.80B | +32.6% | +1.7% | 22.4 | 4.2% |
|
LIN
Linde PLC
|
$214.92B | +9.3% | +3.0% | 30.1 | 1.2% |
|
AIQUF
L Air Liquide SA /Fi
|
$123.25B | +2.9% | — | — | 0.0% |
|
SHW
Sherwin Williams Co
|
$78.49B | -0.2% | +2.1% | 29.8 | 2.9% |
|
ECL
Ecolab Inc.
|
$77.42B | +5.2% | +2.2% | 37.1 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVNT | -3.5% | -10.2% | +29.8% | -6.0% | +32.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.4% | -8.5% | +11.9% | -5.7% | +20.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.